CLX 155

Drug Profile

CLX 155

Alternative Names: Capacetabine/fluorouracil analogue; CLX-155

Latest Information Update: 24 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellix Bio
  • Class Antineoplastics; Carbamates; Pyrimidinones; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer
  • Discontinued Breast cancer; Gastric cancer; Head and neck cancer

Most Recent Events

  • 24 Apr 2018 Discontinued - Preclinical for Head and neck cancer, Breast cancer and Gastric cancer in India (Parenteral) (Cellix Bio pipeline, April 2018)
  • 20 Feb 2018 Preclinical trials in Breast cancer in India (Parenteral), prior to February 2018
  • 20 Feb 2018 Preclinical trials in Colorectal cancer in India (Parenteral), prior to February 2018 (Cellix Bio pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top